FINHUB Insights

REGN · Q1 FY26 · Mar 31, 2026

Regeneron Pharmaceuticals Q1 FY26: where the revenue came from and where it went

Regeneron Pharmaceuticals Q1 FY26: revenue $3.6B (+19% year over year). Net profit $0.7B. Largest cohort Collaboration Revenue $1.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
Apr 29, 2026 10-Q
Sankey diagram of Regeneron Pharmaceuticals's income statement for Q1 FY26: revenue of $3.6 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.6B +19% year over year
Gross profit$1.4B 39% margin
Operating profit$0.6B 18% margin
Net profit$0.7B 20% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 3.6 100% +19%
Collaboration Revenue 1.9 53% +24%
Product 1.5 42% +8%
Product and Service Other 0.2 6% +109%
Cost of revenue−2.261%
Gross profit1.439% margin−5pp
Research & development−0.243%−1pp
SG&A−0.618%−3pp
Operating profit0.618% margin−2pp
Tax−0.1
Net profit0.720%−7pp
Filing on EDGAR More quarters of REGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters